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ABSTRACT
Objective To determine the persistence of bactericidal
antibody titres following immunisation with serogroup C
meningococcal glycoconjugate vaccine at age 6-15 years
in order to examine changes in persistence of antibodies
with age.
Design Observational study.
Setting Secondary and tertiary educational institutions in
the United Kingdom.
Participants Healthy adolescents aged 11-20 years
previously immunised between 6 and 15 years of agewith
one of the three serogroup C meningococcal vaccines.
Intervention Serum obtained by venepuncture.
Main outcome measures Percentage of participants with
(rabbit complement) serum bactericidal antibody titres of
at least 1:8; geometric mean titres of serogroup C
meningococcal serum bactericidal antibody.
Results Five years after immunisation, 84.1% (95%
confidence interval 81.6% to 86.3%) of 987 participants
had a bactericidal antibody titre of at least 1:8. Geometric
mean titres of bactericidal antibody were significantly
lower in 11-13 year olds (147, 95% confidence interval
115 to 188) than in 14-16 year olds (300, 237 to 380) and
17-20 year olds (360, 252 to 515) (P<0.0001 for both
comparisons). Within these age bands, no significant
difference in geometric mean titres of bactericidal
antibody between recipients of the different serogroup C
meningococcal vaccines was seen. More than 70% of
participants had received a vaccine from one
manufacturer; in this cohort, geometric mean titres were
higher in those immunised at aged 10 years or above than
in those immunised before the age of 10.
Conclusions Higher concentrations of bactericidal
antibody are seen five years after immunisation with
serogroup C meningococcal vaccine at age 10 years or
above than in younger age groups, possibly owing to
immunological maturation. This provides support for
adolescent immunisation programmes to generate
sustained protection against serogroup C meningococcal
disease not only for the vaccine recipients but also,
through the maintenance of herd immunity, for younger
children.
INTRODUCTION
In 1999 to 2000 a mass immunisation campaign in the
United Kingdom used three different serogroup C
meningococcal glycoconjugate vaccines. This cam-
paign aimed to administer a single dose of one of the
vaccines to all 1-18 year olds and accompanied the
introduction of the serogroup C meningococcal
vaccines into the routine infant immunisation sche-
dule. Two of the vaccines contained the serogroup C
meningococcal capsular polysaccharide conjugated to
a CRM197 carrier protein (Menjugate, Novartis Vac-
cines andDiagnostics, Siena, Italy;Meningitec,Wyeth
Vaccines, Pearl River, NY, USA), and the third used a
tetanus toxoid carrier protein (NeisVac-C, Baxter
Vaccines, Beltsville, MD, USA). An uptake of more
than 85% was achieved, resulting in a dramatic
reduction in serogroup C meningococcal disease.1
Enhanced surveillance of serogroupCmeningococ-
cal disease and sero-epidemiological studies done after
this campaign have shown the importance of main-
taining adequate concentrations of specific bactericidal
antibody in populations at risk of this disease. Waning
effectiveness after immunisation of infants has been
associated with a fall in the percentage of children with
serum bactericidal antibody titres above the accepted
correlates of protection.2 Children immunised at
2 years of age have shown a similar decline in
seroprotection rates,3 with uncertain effectiveness
beyond one year after immunisation.2 In contrast,
sustained elevation of bactericidal antibody titres has
been shown threeyears after immunisationof 9-12year
olds,4 and this age cohort has no evidence of declining
vaccine effectiveness.2
No data are available on the persistence of post-
immunisation bactericidal antibody titres in children
immunised at 6-8 years of age in the UK mass
immunisation campaign. Whether this age group will
have a sustained increase in their post-immunisation
titres of bactericidal antibody against serogroup C
meningococcus, like their older counterparts, or
whether their immune response will wane like those
of younger children is therefore unknown. This lack of
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data is important given that this cohort is now entering
adolescence, a period that before the introduction of
the vaccines was one of increased risk for serogroup C
meningococcal disease.1 Similarly, no information is
available on the persistence of serum bactericidal
antibody titres after immunisation of 13-15 year olds,
the cohort currently entering young adulthood, or
whether the choice of vaccine influences these mea-
sures of longer term immunogenicity.
We therefore measured the meningococcal ser-
ogroup C specific bactericidal antibody titres and IgG
concentrations in bloodobtained from999 adolescents
aged 11-20 years who were immunised between the
ages of 6 and 15 years. By obtaining the immunisation
records of these participants, we determined whether
persistence of bactericidal antibody titres was influ-
enced by age of immunisation, specific serogroup C
meningococcal immunisation received, or both.
METHODS
Study design and participants
The primary objective of this observational study was
to evaluate the persistence of specific bactericidal
antibody against serogroup C meningococcus in
participants aged 11-20 years who received one dose
of Menjugate during the 1999 to 2001 vaccination
campaign. We did the study in Buckinghamshire and
Oxfordshire betweenMarch andDecember 2005.We
invited adolescents aged 11-20 attending secondary
schools or higher educational establishments to parti-
cipate, by letter or advertisement. Participants were to
be in good health and provide a parental report or self
report of having received one of the serogroup C
meningococcal vaccines in theUKmass immunisation
campaign. Exclusion criteria included immunosup-
pression, pregnancy, severe medical illness, antibiotic
use within 14 days of enrolment, and previous
confirmed invasive meningococcal disease. Of the
999 participants to be recruited, at least 100 were to be
14-16 year olds (inclusive) who had been immunised
with the serogroup C meningococcal vaccine Menju-
gate. This cohort was to act as agematched controls for
participants recruited in a previous study.4 For
participants aged under 16, consent was given by a
parent and the participant; those aged16or above gave
consent themselves.
After enrolment, we took up to 10 ml of blood and
confirmed previous serogroup C meningococcal
immunisation by reference to the participant’smedical
records or the centralised immunisation records of the
child health computer departments. We noted details
of the age at immunisation and which of the three
serogroup C meningococcal vaccines was used when
this information was available. In addition, for
Menjugate recipients aged 9 and 10 years at serogroup
C meningococcal immunisation (14-15 years old at
enrolment), we noted details of the receipt of the
“school leaver booster” vaccine (combined diphtheria
and tetanus vaccine).
Serological responses
The Vaccine Evaluation Unit, Manchester, analysed
serum for bactericidal antibody by using strain C11
(phenotype C:16:P1.7-1,1). Baby rabbit serum (Pel-
Freeze, Rodgerson, AZ, USA) was used as an
exogenous complement source. Titres of serum
bactericidal antibody were expressed as the reciprocal
serum dilution yielding 50% or greater killing after
60 minutes. The putative protective rabbit comple-
ment serum bactericidal antibody titre (that is,
seroprotection) is at least 1:8, but the study protocol
specified an additional, conservative, criterion of a
rabbit serum bactericidal antibody titre of at least
1:128.Wedetermined the serogroupCmeningococcal
polysaccharide specific IgG concentration by enzyme
linked immunosorbent assays (ELISAs) at Oxford
University, using apreviously describedmethod.5 Staff
at both laboratories were blinded to the participant’s
age and the vaccine received.
Statistical analysis
The analysis of this observational study was descrip-
tive, and we did no formal calculations of study power
for the primary objective. We specified a recruitment
target of up to 1000 participants in order to provide
adequate numbers to obtain information on the
Table 1 | Recruitment summary
Event No
Letters sent 10 949
Replies received 1594
Responded “No” 353
Responded “Yes” 1241
“Yes” responses subsequently excluded 242*
Patients enrolled 999
Patients included in immunogenicity
analysis
987†
*Reasons for exclusion were changed mind to “No”(58), recruitment to
study already complete (40), out of age range (2), current antibiotic use
(15), recent/planned further immunisation (17), meningococcal
serogroup C vaccine naive status reported (47), medical history (17),
moved out of area (1), unable to contact (43), and other (2).
†11 participants did not have history of immunisation with
meningococcal serogroup C confirmed; one participant did not have
blood drawn.
Table 2 | Demographics and vaccine received for participants included in immunogenicity
analysis. Values are numbers (percentages) unless stated otherwise
Characteristic
Age band
11-13 years
(n=407)
14-16 years
(n=410)
17-20 years
(n=170) All ages (n=987)
Male 235 (58) 224 (55) 78 (46) 537 (54)
Mean (SD) age (years) 12.8 (0.63) 15.4 (0.85) 18.0 (0.85) 14.8 (2.02)
Mean (SD) age at
immunisation (years)
8.1 (0.64) 10.4 (0.77) 12.7 (0.84) 9.9 (1.81)
Mean (SD) time since
immunisation (years)
4.7 (0.22) 5.0 (0.30) 5.3 (0.23) 4.9 (0.34)
Vaccine received
NeisVac-C 65 (16) 31 (8) 0 96 (10)
Menjugate 275 (68) 297 (72) 136 (80) 708 (71)
Meningitec 41 (10) 32 (8) 22 (13) 95 (10)
Unknown 26 (6) 50 (12) 12 (7) 88 (9)
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persistence of seroprotection across all age bands and
for all three serogroup C meningococcal vaccines.
We did immunogenicity analyses for Menjugate
recipients only and for recipients of the other
serogroup C meningococcal vaccines. We analysed
immunogenicity data for the whole immunised popu-
lation and also stratified by age bands based on age at
recruitment: 11-13 years, 14-16 years, and 17-20 years.
We calculated geometric mean titres of serogroup C
meningococcal bactericidal antibody and geometric
mean concentrations of meningococcal serogroup C
specific IgG for the above populations, as well as the
percentage of participants with rabbit serum bacter-
icidal antibody titres of at least 1:128 and at least 1:8.
We also calculated the 95% confidence intervals for
these measurements. In an exploratory analysis, we
used analysis of variance to compare thesemeasures of
immunogenicity between recipients of the different
vaccineswithin the sameagebandand, for recipients of
the same vaccine, within different age bands.Wemade
corrections for the multiple comparisons by the
Bonferroni method.
We also explored persistence of antibody after
immunisation with Menjugate by calculating the
geometric mean bactericidal antibody titres, IgG
geometric mean concentrations, and the percentage
of Menjugate recipients who were seroprotected, after
stratification according to their year of age at immuni-
sation. We used a multiple regression analysis for
geometric mean bactericidal antibody titres and
geometric mean IgG concentrations to assess the
impact of age at immunisation, adjusting for the
clustering effect of the school/campus attended, the
years since immunisation, and the batch number of
Menjugate received and the potential confounding
factor of sex. We used multiple logistic regression to
evaluate the impact of age at immunisation on the
percentage of participants seroprotected, adjusting for
the same covariates. For the purposes of analysis by
year of immunisation, we pooled the results of those
immunised at age 6 and 7 in view of the smaller
numbers in these cohorts, aswell as those immunisedat
ages 12-15. We used SPSS version 14.0 and Microsoft
Excel to analyse data. We used Stata version 9.2 for
multiple regression analysis.
RESULTS
We recruited a total of 999 participants from 22
educational institutions (median number of
participants per school/campus 13, range 1-174). As
outlined in table 1, we evaluated immunogenicity
results for 987 participants. The mean age of these
participants was 14.8 (SD 2.02) years, and the mean
time since immunisation was 4.9 (SD 0.34) years.
Table 2 shows further demographic details.
Antibody persistence in Menjugate recipients according to
age at enrolment
Of the 987 participants, 708 (72%) had received
Menjugate (mean age 15.0 (SD 2.04) years). Mean
time since immunisationwas 4.9 years and tended tobe
slightly longer in older age bands (4.7 years in
11-13 year olds, 5.0 years in 14-16 year olds, and 5.
3 years in 17-20 year olds). Serum bactericidal
antibody titres of at least 1:8 were shown by 83.3%
(95% confidence interval 80.4% to 86.0%) of Menju-
gate recipients (table 3). When analysed according to
age band, the geometric mean bactericidal antibody
titres, geometric mean IgG concentrations, and per-
centage of participants with bactericidal antibody titres
of at least 1:8 and at least 1:128 were all significantly
lower in 11-13 year old Menjugate recipients than in
14-16 year olds and 17-20 year olds.
Antibody persistence in Menjugate recipients according to
age at immunisation
In order to assess more directly the influence of age on
the immune response,we analysed the abovemeasures
of immunogenicity according to year of immunisation
(fig 1, tables 4 and 5). Whereas the geometric mean
bactericidal antibody titres were relatively consistent
for participants immunised at age 6-9 years, we saw a
marked increase in geometric mean bactericidal anti-
body titres in those immunised at age 10 (table 4). This
was then again relatively consistent for those immu-
nised at older ages. We saw similar, although less
marked, trends in seroprotection levels. We also saw a
trend to increasing geometric mean serogroup C
meningococcal IgG concentrations with increasing
age at immunisation (table 4), with a less clear
demarcation in antibody concentration between
years 9 and 10 than was seen with the geometric
mean bactericidal antibody titres.
We further analysed this trend by multiple regres-
sion analysis, adjusting for sex, time since immunisa-
tion, the batch number of Menjugate received, and the
clustering effect of school/campus attended. As shown
in table 4, even after adjustment for these factors,
Table 3 | Markers of immunogenicity forMenjugate recipients. Values in parentheses are 95%confidence intervals
Marker
Age band (age at blood sampling)
11-13 years (n=275) 14-16 years (n=297) 17-20 years (n=136) All ages (n=708)
SBA titre ≥1:8 (%) 76.4 (70.9 to 81.2)* 87.5 (83.2 to 91.1) 88.2 (81.6 to 93.1) 83.3 (80.4 to 86.0)
SBA titre ≥1:128 (%) 65.1 (59.1 to 70.7)† 75.1 (69.8 to 79.9) 77.9 (70.0 to 84.6) 71.8 (68.3 to 75.0)
SBA GMT 124 (91 to 170)‡ 312 (236 to 413) 346 (232 to 516) 222 (184 to 269)
IgG GMC (μg/ml) 1.1 (0.9 to 1.3)‡ 2.6 (2.1 to 3.3) 3.6 (2.6 to 4.9) 1.9 (1.7 to 2.2)
GMC=geometric mean concentration; GMT=geometric mean titre; SBA=serum bactericidal antibody.
*P=0.001 for comparison with 14-16 year old age band; P=0.007 for comparison with 17-20 year old age band.
†P=0.02 for comparison with 14-16 year old age band; P=0.02 for comparison with 17-20 year old age band.
‡P<0.0001 for comparisons with14-16 and 17-20 year old age bands.
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participants immunised at age 6-7, 8, or 9 years of age
had significantly lower geometric mean bactericidal
antibody titres than those immunised at ages
12-15 years. By contrast, we found no significant
difference in the geometricmean bactericidal antibody
titres between participants immunised at 10 and
11 years and those immunised at 12-15 years, again
supporting an increment in serogroup C meningococ-
cal bactericidal antibodies in those immunised with
Menjugate at 10 years of age or above, independent of
sex, time since immunisation, batch number received,
or clustering effects of school/campus attended. We
saw the same increment when we analysed the
percentage of participants achieving bactericidal
antibody titres of at least 1:128 by logistic regression
(again correcting as above) (table 5).
We considered receipt of the “school leaver”
combined diphtheria and tetanus vaccine as another
possible confounding factor. For those Menjugate
recipients for whom we had data, only 20 of 66 aged
9 years at serogroup C meningococcal immunisation
had received a booster dose of diphtheria and tetanus
vaccine before enrolment, compared with 100 of 108
children aged 10 years at time of immunisation. The
close relation between age at immunisation and like-
lihood of receipt of the school leaver vaccine before
enrolmentmeant that we could not analyse the relation
between the receipt of this vaccine and the geometric
mean bactericidal antibody titres and geometric mean
IgG concentrations independent of age at immunisa-
tion.
Antibody persistence in all serogroup C meningococcal
vaccine recipients according to age at enrolment
We extended analysis of immunogenicity to all 987
participants with confirmed history of receipt of any of
the three serogroup C meningococcal vaccines. This
showed a meningococcal serogroup C bactericidal
antibody titre of at least 1:8 in 830 participants (84.1%,
81.6% to 86.3%). Table 6 shows further measures of
immunogenicity for all ages and according to age band
(irrespective of vaccine received).
In further analysis for impact of age at enrolment on
these measures in non-Menjugate recipients, we saw a
non-significant tendency to lower geometric mean
bactericidal antibody titres in 11-13 year olds than in
14-16 year olds and 17-20 year olds for Meningitec
recipients and to lower geometric mean bactericidal
antibody titres in 11-13 year olds than 14-16 year olds
for NeisVac-C recipients (fig 2).
We also analysed the geometric mean titres of
serogroup C meningococcal bactericidal antibody
and geometric mean concentrations of IgG for each
vaccine separately within each age band (figs 2 and 3).
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Fig 1 | Meningococcal serogroup C (MenC) specific serum
bactericidal antibody geometric mean titre (SBA GMT) after
Menjugate immunisation, by age of immunisation
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Fig 2 | Meningococcal serogroup C (MenC) serum bactericidal
antibody geometric mean titre (SBA GMT) after receipt of MenC
vaccine, by age band at blood sampling and vaccine received.
No participants in 17-20 year age band received NeisVac-C
Table 4 | Multiple regression analysis formeningococcal
serogroup C specific serumbactericidal antibody geometric
mean titres and IgG geometricmean concentrations after
immunisationwithMenjugate at ages 6-7, 8, 9, 10, and
11 years, comparedwith immunisation at 12-15 years
Age at
immunisation
(years)
Estimated relative difference*
(robust 95% CI) P value
Serum bactericidal antibody geometric mean titres
Overall – <0.001
6-7 0.28 (0.12 to 0.66) 0.005
8 0.23 (0.10 to 0.52) 0.001
9 0.27 (0.11 to 0.69) 0.01
10 0.73 (0.32 to 1.71) 0.4
11 0.84 (0.51 to 1.37) 0.5
12-15 Reference –
IgG geometric mean concentrations
Overall – <0.001
6-7 0.26 (0.14 to 0.47) <0.001
8 0.42 (0.27 to 0.65) <0.001
9 0.48 (0.30 to 0.75) 0.002
10 0.70 (0.41 to 1.21) 0.2
11 0.90 (0.62 to 1.29) 0.5
12-15 Reference –
*Adjusted for sex, years since immunisation, batch of Menjugate
received, and clustering effect of school/campus attended.
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For 11-13 year olds we saw a tendency for Menjugate
recipients to have a lower geometric mean bactericidal
antibody titres (124, 95%confidence interval 91 to 170)
than recipients of NeisVac-C (256, 151 to 433) or
Meningitec (243, 120 to 493). However, analysis of the
impact of vaccine received on geometric mean titres of
serogroup C meningococcal bactericidal antibody
within this age group revealed no significant differ-
ences (P=0.1 forMenjugate comparedwithNeisVac-C
and P=0.3 for Menjugate compared with Meningitec).
This trend was less obvious when we compared the
percentage of participants with bactericidal antibody
titres of at least 1:128 (fig 4) or those with bactericidal
antibody titres of at least 1:8 (data not shown) or
geometric mean IgG concentrations (fig 3).
DISCUSSION
Key findings
The data presented here show that protective concen-
trations of antibody persist better after immunisation
with a serogroup C meningococcal vaccine in the
second decade of life than in the first decade. Whereas
most of the 11-20 year olds in this study retained
meningococcal serogroup C bactericidal antibody
titres of at least 1:128 at a mean of 4.9 years after
immunisation, approximately 10%more achieved this
correlate of protection in the 14-16 and 17-20 year old
Menjugate recipient cohorts than in the 11-13 year
olds. Geometric mean titres of bactericidal antibody
among Menjugate recipients were similarly higher in
the older age groups. These trends were also apparent
for geometric mean titres of bactericidal antibody and
IgG concentrations after receipt of the other serogroup
C meningococcal vaccines but did not reach statistical
significance (possibly owing to smaller sample sizes).
Previous studies have shown that one year after a
primary course ofmeningococcal serogroupCvaccine
at 2, 3, and 4 months of age only 46% of children had
serum bactericidal antibody titres of at least 1:8; this
had fallen to 12% four years after immunisation.6
Similarly, after immunisation at age 1-3 years bacter-
icidal antibody titres of at least 1:8 were seen in the
serum of only 27% of vaccinees two years after
immunisation and only 25% three years after
immunisation.37 By contrast, in this study 75.5% of
the children immunised at age 6-7 years had serum
bactericidal antibody titres of at least 1:8 at a mean
period of 4.7 years after immunisation. In addition, we
have described for the first time an increment in the
persistence of bactericidal activity that is present
among participants immunised from 10 years of age.
Increasing age of immunisation beyond 10 years,
however, seems to make little further difference to the
bactericidal activity seen.
The duration of seroprotection in the years after
serogroup C meningococcal immunisation is particu-
larly relevant given that persistence of bactericidal
antibody, rather than the anamnestic response to
subsequent antigen challenge, is likely to be of primary
importance in determining the long term effectiveness
of meningococcal serogroup C vaccines.2 8 A similar
dependence on antibody persistence has been shown
for the Haemophilus influenzae type b glycoconjugate
vaccines,9 suggesting that this is likely to be relevant for
all the glycoconjugate vaccines.
Explanations for findings
The age dependent variations in bactericidal antibody
concentrations thatwehavedescribedheremaybedue
to participants in the older age groups having had a
Table 6 | Percentagewith serogroupCmeningococcal specific serumbactericidal antibody (SBA)
titres≥1:8and≥1:128,SBAgeometricmeantitres(GMT),andIgGgeometricmeanconcentrations
(GMCs) of all participants included in immunogenicity analysis (regardless of serogroup C
meningococcal vaccine received). Values in parentheses are 95%confidence intervals
Age band (age at blood sampling)
11-13 years
(n=407)
14-16 years
(n=410)
17-20 years
(n=170) All ages (n=987)
SBA ≥1:8 (%) 79.1 (75.1 to 83.0) 87.3 (84.1 to 90.5) 88.2 (83.4 to 93.0) 84.1 (81.6 to 86.3)
SBA ≥1:128 (%) 68.0 (63.3 to 72.6) 75.4 (70.9 to 79.5) 79.4 (72.5 to 85.2) 73.0 (70.2 to 75.8)
SBA GMT 147 (115 to 188) 300 (237 to 380) 360 (252 to 515) 231 (198 to 270)
IgG GMC (μg/ml) 1.2 (1.0 to 1.4) 2.5 (2.1 to 3.0) 3.6 (2.7 to 4.6) 2.0 (1.7 to 2.2)
Table 5 | Logistic regression analysis for percentage of
participants achieving serumbactericidal antibody titres
≥1:128afterimmunisationwithMenjugateatages6-7,8,9,10,
and 11 years, comparedwith immunisation at 12-15 years
Age at immunisation
(years)
Odds ratio (robust
95% CI) P value
Overall – <0.001
6-7 0.35 (0.16 to 0.73) 0.005
8 0.38 (0.19 to 0.74) 0.005
9 0.34 (0.16 to 0.74) 0.01
10 0.70 (0.41 to 1.20) 0.2
11 0.96 (0.63 to 1.49) 0.9
12-15 Reference –
*Adjusted for sex, years since immunisation, batch of Menjugate
received, and clustering effect of school/campus attended.
Age band at blood sampling (years)
11-13 14-16 17-20
0
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Fig 3 | Meningococcal serogroup C (MenC) specific IgG
geometric mean concentration (GMC) after receipt of MenC
vaccine, by age band at blood sampling and vaccine received.
No participants in 17-20 year age band received NeisVac-C
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greater response than those in younger age groups to
the initial immunisation against serogroup C menin-
gococcus. This was seen in a study in which the
response to the three serogroup C meningococcal
vaccines was 1.3 to 3.7 times higher in adolescents
(mean age 15.1 years) than in younger children (mean
age 4.3 years).10Alternatively, itmaybe due to a slower
subsequent decline in antibody titre. As outlined
below, immunological maturation is a possible expla-
nation for both these phenomena. Alternatively,
greater rates of nasopharyngeal carriage of serogroup
C meningococcal bacteria (or exposure to cross
reactive organisms) may result in greater priming or
boosting of the response to the serogroup C meningo-
coccal vaccine in the older age groups. In addition,
other, non-immunological, explanations such as sys-
tematic biases in our study (for example, an effect of the
school attended, independent of the age at vaccine
receipt) need to be considered and are also discussed
below.
Immunological maturation through early childhood
is well described. Suggested mechanisms include the
waning of maternal antibody,11 the developing ability
to generate germinal centres after antigenic stimulation
(in turn influencing the initial B cell and antibody
response),12 and increased availability of bonemarrow
niches for long lived plasma cells (postulated to be
relevant to the persistence of specific antibody).13 Our
study suggests the possibility that further, previously
unrecognised, maturation of the immune response to
the serogroup C meningococcal polysaccharide cap-
sule occurs in the second decade of life.
Another possible explanation for the greater bacter-
icidal antibody concentrations in participants immu-
nised at age 10 or above is that these cohorts have
experienced a greater degree of immune priming or
boosting through nasopharyngeal carriage of ser-
ogroup C meningococcus than those immunised at
anearlier age.Mostof the children immunisedat age10
would have been entering secondary school within a
year after the introduction of the serogroup C
meningococcal vaccines. Adolescence is the age of
peak nasopharyngeal carriage of serogroup C menin-
gococcus, and, although cross sectional surveillance
studiesdonebefore the introductionof the serogroupC
meningococcal vaccine suggest a carriage rate of only
0.45% in 15-17 year olds,14 studies in the pre-
vaccination era showed this to be the age of peak
carriage.15 16 Also, longitudinal studies might show
broader population exposure to the organism. Given
the rapid decline in rates of nasopharyngeal carriage of
serogroup C meningococcus in the year after the
introduction of serogroup Cmeningococcal vaccine,14
children immunised at age 10 or abovemight have had
more natural exposure to serogroupCmeningococcus
than those entering secondary school in subsequent
years. This provides an alternative explanation for the
transition to higher bactericidal titres in this age group.
Immunological priming by exposure to cross reactive
antigens such as Escherichia coli K92 has also been
suggested as a factor in the greater response to
meningococcal polysaccharides with increasing
age.417
The existence of better immune responses to the
meningococcus in older children is supported by both
the UK effectiveness studies of the serogroup C
meningococcal glycoconjugate vaccines andCanadian
studies of the effectiveness of the plain polysaccharide
serogroup C meningococcal vaccines.2 18 The Cana-
dian studies showed a strong trend to increased
effectiveness for children immunised at ages 10-14
(effectiveness 75%, 95% confidence interval −17% to
93%) comparedwith those immunised at ages 2-9 years
(effectiveness 41%, −106% to 79%).
Comparisons with previous studies
The influence ofmaturation from the first to the second
decade of life on the immune response to other
vaccines varies. After immunisation with a 14-valent
pneumococcal plain polysaccharide vaccine,
11-12 year old children tended to generate higher
geometric mean concentrations of IgG specific to
serotypes 14, 18C, 19F, and 23F than did 8-10 year old
children,19 but this was not replicated in a subsequent
study.20 The antibody response and persistence after
immunisation with hepatitis A vaccine were no greater
in 9-14 year old children than 4-6 year olds.21 Likewise,
a booster dose of measles, mumps, and rubella vaccine
elicited similar responses in 4-6 year olds and
11-13 year olds,22 whereas responses to varicella
immunisation are relatively impaired in adolescence
compared with early childhood.23 These studies
suggest that the development of the response to
immunisation in the second decade of life depends on
the nature of the stimulating antigen as well as age
related factors. We are not aware of any studies
assessing the maturation of the immune response to
other glycoconjugate vaccines in the years around
puberty.
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Fig 4 | Percentage of participants with serum bactericidal
antibody (SBA) titres ≥1:128 after meningococcal serogroup C
(MenC) immunisation, by age band and vaccine received. No
participants in 17-20 year age band received NeisVac-C
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Strengths and weaknesses of the study
The possibility that the increase in persistence of
serogroup C meningococcal bactericidal titres seen in
this study in children aged over 10 was due to factors
other than immunological maturation or differences in
priming/boosting needs consideration. No systematic
bias in the collection, handling, or analysis of the blood
samples couldbe identified.The similarityof the trends
seen between serum bactericidal activity and IgG
assays, done in different laboratories by staff blinded to
the ages of participants, suggests that no bias in the
laboratory analysis was present. In addition, the
increase in bactericidal antibodies seen was indepen-
dent of sex or clustering due to the school or campus
attended, the batch number of Menjugate received, or
the time between immunisation and blood sampling.
We considered receipt of the school leaver booster
diphtheria and tetanus vaccine (routinely administered
at approximately 14 years of age in the UK, and
therefore more commonly received by those immu-
nised against serogroup C meningococcus five years
previously at 10 years of age than those immunised at
age 9) as another possible confounding factor. In this
respect, we should note that the carrier protein used by
Menjugate (CRM197) is a mutant of diphtheria toxoid.
However, because of the close relation between age at
immunisation and receipt of the diphtheria and tetanus
booster vaccine, we could not analyse independently
the impact of receipt of this vaccine. That said,
stimulation of B or T cells specific to the carrier protein
would seem unlikely to also result in the stimulation of
B cells specific for the conjugated polysaccharide
capsule, except as part of a non-specific bystander
effect as suggested by some authors.24 Finally, the lack
of a control group who had not received serogroup C
meningococcal vaccine raises the possibility that the
age dependent differences seen relate to acquisition of
natural immunity. However sero-epidemiological stu-
dies done before the introduction of the serogroup C
meningococcal vaccine in theUKshowed serogroupC
meningococcal bactericidal antibody titres of at least
1:128 in only 5-10% of 10-19 year olds,25 suggesting
that this is unlikely.
This study was designed to assess the persistence of
seroprotection afforded by the serogroup C
meningococcal vaccines and not as a sero-epidemio-
logical study.We therefore aimed to selectively recruit
serogroup C meningococcal vaccine recipients, rather
than a cohort representative of all 11-20 year olds in the
UK. Nevertheless, given that the UK mass immunisa-
tion campaign achieved coverage rates of greater than
85% in most targeted cohorts,1 the figures we report
here are unlikely to greatly overestimate seroprotec-
tion levels in the community. Most adolescents and
young adults in the UK therefore seem to have
bactericidal antibody concentrations above even the
strictest correlate of protection. However, a significant
minority lack seroprotection against serogroup C
meningococcal disease; among those aged
11-13 years at the time of this study, this figure is
more than 20% and presumably will continue to grow
with increased time since immunisation.
Clinical relevance
The new routine immunisation schedule introduced in
the UK in September 2006 provides a booster dose of
vaccine against serogroup Cmeningococcal disease in
the second year of life and is likely to improve
persistence of antibodies, but no population data are
available to indicate the longer term success of this new
strategy. However, we know that the previous primary
schedule did not induce persistence of protective
concentrations of bactericidal antibody. Over the
next five years, a cohort of children with very low
levels of serogroup C meningococcal seroprotection,
who received primary immunisation in early child-
hood without a booster dose, will be entering
adolescence in the UK. This cohort will be susceptible
not only to invasive meningococcal disease but also to
nasopharyngeal carriage of serogroup C meningococ-
cus. The herd immunity that is currently indirectly
protecting those with low antibody concentrations is
therefore likely towane.Accordingly, we suggest that a
booster dose of serogroup C meningococcal vaccine
administered in early adolescence would be appro-
priate for this cohort. On the basis of this study, we can
beconfident that this boosterdosewouldmaintainhigh
concentrations of bactericidal antibodies through
adolescence and into early adulthood, regardless of
which serogroup C meningococcal vaccine is used.
This should in turn provide protection not only to the
vaccine recipients but also, through maintenance of
herd immunity, to the younger children who have not
received booster doses and among whom direct
vaccine effectiveness is negligible.
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